Single-Use Bioreactors Market expected to reach US$7.258 billion by 2030

single-use bioreactors market

Single-Use Bioreactors Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the single-use bioreactors market will expand from USD 5.462 billion in 2025 to USD 7.258 billion in 2030 at a CAGR of 14.55% during the forecast period.

Single-use bioreactors in the SAFS represent a transformative shift within Biopharmaceutical manufacturing, replacing stainless steel systems with disposable, pre-sterilized plastic bags and components. These systems allow flexible production while ensuring sterile conditions for the manufacture of biologics, vaccines, and cell therapeutics, which reduces cleaning validation time and costs.

The advent of this change is the biopharmaceutical boom, with worldwide biologics sales growing on an annual basis. Monoclonal antibodies take precedence among the spectrum of applications for single-use bioreactors because they promise the highest revenues within treatments for cancer and autoimmune diseases. Cell and gene therapies demand the modular flexibility of single-use bioreactors for low-volume, high-value manufacturing, with FDA approvals fueling their growth at a fabulous pace. Cost savings-further installation costs that would be attractive to contract manufacturing organizations. Regulatory impetus for sustainability and shortened time-to-market time enhances adoption; single-use bioreactors practically slash water and energy consumption by almost that rate as reusable systems. Many opportunities for AI-integrated bioreactors would provide real-time optimization and hybrid models mixing single-use bioreactors with reusables.

Request a free sample copy or view the report summary: Single-Use Bioreactors Market Report

Single-Use Bioreactors Market Report Highlights

  • The Single-Use Bioreactor Systems segment is expected to attain a major market share by 2030, driven by its increased scalability from utilization in research and development to commercialization. It requires decreased validation and diverse filtration assemblies’ usage for sterility in regulatory and integration in the downstream. The increasing shift towards pre-sterilization practices and in sensor-integrated assemblies is increasing this segment among biobased companies for increasing sustainability.
  • The mammalian cell is estimated to hold the largest share in the cell type segment during the forecasted period. This is due to its leading role in the production of biologics like cells for antibodies in the biopharmaceutical sector. The growing penetration of these cell cultures in applications for development in clinical trials and the pipeline, and increased compatibility that decreases contamination in sensitive processing.
  • The monoclonal antibodies segment is the vast segment in the molecular type of the single-use bioreactors market. The monoclonal antibodies a widely used in diverse disease evaluations, like autoimmune diseases, infectious treatments, and oncology, which increases the demand for single-use bioreactors. Meanwhile, the vaccine is holding a considerable share, which promotes production requirements and pandemic-driven requirements.
  • The pharmaceuticals and biopharmaceuticals segment is a major segment in the end-user of this market. They utilize single use bioreactors widely in increased production of biologics and extensive investment for research and development of new biologics, also increasing the demand for single-use bioreactors. The financing and seamless scaling in mAbs, therapies, and vaccines manufacturing also boost the adoption of the market in the coming years.
  • North America is driving the single-use bioreactors market due to the strong healthcare and biopharma infrastructure in the region. Furthermore, the presence of major players such as Thermo Fisher also boosts the regional market, along with increased research and development investment by the regional firms. These will also boost the adoption og single-use bioreactors for biologics production in the region.

Report Coverage:

Report Metric Details
Market Size Value in 2025 US$5.462 billion
Market Size Value in 2030 US$7.258 billion
Growth Rate CAGR of 14.55%
Drivers
  • Growing Demand for Vaccines and Biologics
  • Robust Adoption in Contract Development & Manufacturing Organization
Restraints
  • Consumable cost and Operating Expense Profile
  • Concern related to Waste Management
Segments Covered
  • Product Type
  • Cell Type
  • Molecule Type
  • End-User
  • Geography
Companies Covered
  • ABEC Inc.
  • Celltainer
  • Distek Inc.
  • Eppendorf AG
  • GE Healthcare

Single-Use Bioreactors Market Growth Drivers and Restraints

Growth Drivers:

  • Growing Demand for Vaccines and Biologics: The rise in demand for biologics like recombinant proteins and mAbs, antibiotics, and vaccines, along with personalized gene therapies, demands an effective and flexible manufacturing process and a fast time for clinical development. This is increasing the demand for these single-use bioreactors, which are faster and have a lower cost overall while offering sustainability due to decreased carbon footprint caused by them. Hoch is promoting its adoption among manufacturers.
  • Robust Adoption in Contract Development & Manufacturing Organization: the stringent contract development and manufacturing organization adoption and focus on the single-use bioreactors and their associated platforms for supporting the utilization and flexibility is also promoting the market.

Restraints:

  • Consumable cost and Operating Expense Profile: The increased cost in the disposable materials like sensors, connectors, and bags can be costly even though the initial capital is lower, which could hinder their wider adoption.
  • Concern related to Waste Management: the single-use bioreactors produce a large amount of plastic waste in the form of bags, tubing, and other disposables, which can create a sustainability concern.

Single-Use Bioreactors Market Key Development

  • Product Launch: In April 2025, Thermo Fisher Scientific unveiled the 5L DynaDrive Single-Use Bioreactor to align with the changing requirements of modern biopressing. It provides continuous scalability from 1 to 5,000 liters, and a growth in bench scale processing and development, and offers cost-effectiveness.
  • Product Launch: In March 2025, Cytiva widens Xcellerex X-platform for increasing the scalability from 50 liters to 2,000 liters to meet the rising requirements for regulatory-approved products and clinical trials.

Single-Use Bioreactors Market Segmentation

Knowledge Sourcing Intelligence has segmented the Single-Use Bioreactors Market based on product type, cell type, molecular type, end-user, and region:

Single-Use Bioreactors Market, By Product Type

  • Single-Use Bioreactor Systems
  • Media Bags
  • Filtration Assemblies
  • Other Products

Single-Use Bioreactors Market, By Cell Type

  • Mammalian cell
  • Bacteria
  • Yeast
  • Other Cell Types

Single-Use Bioreactors Market, By Molecular Type

  • Monoclonal Antibodies
  • Vaccines
  • Stem Cells
  • Gene-modified Cells
  • Other Molecule Types

Single-Use Bioreactors Market, By End User

  • Pharmaceutical and Biopharmaceutical industries
  • Contract Research Organisations
  • Other End-Users

Single-Use Bioreactors Market, By Region

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

Single-Use Bioreactors Market Key Players

  • ABEC Inc.
  • Celltainer
  • Distek Inc.
  • Eppendorf AG
  • GE Healthcare
  • Thermo Fisher Scientific
  • Parker Hannifin
  • Danaher
  • PBS Biotech
  • Cellexus
  • Applikon Biotechnology